Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. - Test2 - elhamkhani - TriplyDB

Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo.

Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo.

http://www.wikidata.org/entity/Q34546048

about

Sphingolipids: a potential molecular approach to treat allergic inflammation Crystal structure of a lipid G protein-coupled receptor Actions of a picomolar short-acting S1P₁ agonist in S1P₁-eGFP knock-in mice FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated egress The emerging role of FTY720 (Fingolimod) in cancer treatment Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes The role of sphingosine-1-phosphate in endothelial barrier function Lipid phosphate phosphatase (LPP3) and vascular development Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations On-lattice simulation of T cell motility, chemotaxis, and trafficking in the lymph node paracortex Exit Strategies: S1P Signaling and T Cell Migration FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis Development of oral immunomodulatory agents in the management of multiple sclerosis Lipid receptor S1P₁ activation scheme concluded from microsecond all-atom molecular dynamics simulations Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?Sphingosine-1-Phosphate Induces Dose-Dependent Chemotaxis or Fugetaxis of T-ALL Blasts through S1P1 Activation Pathophysiological Consequences of a Break in S1P1-Dependent Homeostasis of Vascular Permeability Revealed by S1P1 Competitive Antagonism Hypoxic preconditioning induces stroke tolerance in mice via a cascading HIF, sphingosine kinase, and CCL2 signaling pathway Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and/or 3 Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.Memo has a novel role in S1P signaling and is [corrected] crucial for vascular development.Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate.Characterization of a sphingosine 1-phosphate receptor antagonist prodrug Sphingosine 1-phosphate chemical biology International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs.Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist.Engineering vascularized tissues using natural and synthetic small molecules Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Cortical sinus probing, S1P1-dependent entry and flow-based capture of egressing T cells Choreography of cell motility and interaction dynamics imaged by two-photon microscopy in lymphoid organs B lymphocytes exit lymph nodes through cortical lymphatic sinusoids by a mechanism independent of sphingosine-1-phosphate-mediated chemotaxis.A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis.Fingolimod treatment in multiple sclerosis leads to increased macular volume.A role for LFA-1 in delaying T-lymphocyte egress from lymph nodes.

P2860

Q21296721-832D70FB-3EA1-4817-8BB1-3AE2975E3767 Q24305457-73B9FCD8-8C5A-4A07-8135-A89D1CCEA29C Q24609856-0F1195C6-1A87-4315-95D9-8D20068096B6 Q24643383-17FDE165-96D6-4E19-BC4B-47E228A89948 Q24646942-8A829871-3362-4A66-BE38-EC7A4BED6E51 Q24650866-71A82D63-E953-4DAE-AFB5-CEF1AC263A43 Q24679761-1DBAFD32-AC5C-429C-B304-C7D320D9D7AF Q26748927-95D1A4F2-E1C7-4553-9F6F-2787BED8B1F5 Q26829985-CBE9FDDB-0C8E-4DB2-A4A3-646B4C0355CE Q26862336-FE8E8220-C4F0-42A2-A183-417BF23D2CD7 Q27002640-9BAD7419-EA05-46D9-B3E9-DF3FD17DFB0C Q27009220-3D18B9D3-40DD-44BF-AFF7-49B7B0214C21 Q27318400-BEE7AB1E-A0C3-4D2A-8147-466EBF463417 Q28081129-F2D15295-5FB4-4C42-B5F3-B20EB2E8D9E9 Q28288357-E4960013-E69B-4ACA-A075-11510C83AA31 Q28388704-651B48E4-CD11-4935-B2F5-F52509EB2C73 Q28534072-63F8408D-6E82-42AA-9F27-2BC8F06EADED Q28546716-21DC408A-C815-4B12-9145-62F081B100E1 Q28552969-82D3BBFF-BF96-4558-B540-EA0572686DE7 Q28555184-362A7A2F-6877-4311-89C4-E982DBE93A36 Q28593650-44E812E0-C05F-482A-B2A9-EA045D456B9B Q30405763-C69E56CB-B084-4B28-BD69-9946B152E990 Q30410634-DFE825B0-658E-4721-972B-C748544E321F Q30413877-1254F2E6-C020-4852-890A-299D6CB38014 Q30423337-2C8AFD9B-A0D5-491E-BD52-9F218B8BF47F Q30425227-9A45BB42-960D-4CB6-9275-870AE6D8156C Q30425603-EFDAACA5-07BC-48BC-9DA4-468885763D66 Q30429523-4E7CA307-F2E8-4C2B-86B5-E18081EAB654 Q30435057-85596285-9F6E-4AB1-ACFB-10B26CB1CDF0 Q30435674-0561929F-6C17-4672-92EA-6F4B171C2B7D Q30439954-108FC9AD-90E7-4B85-B2B4-0F950EE276A0 Q30440476-EB4C00B8-6A55-4939-8E05-DC6337C43F0E Q30442170-E9E8D7D0-55BE-4C8D-905D-7F254D36DD9E Q30486707-C24830A2-1E88-4109-A712-91B94541B47E Q30488797-31BC9CB2-354A-4700-BFA2-F8FE0B7EF8A8 Q30489790-769DF4AF-1E51-4CDD-90AE-F32BE1F21154 Q30490219-5214DF24-342B-4CCD-B743-EBDF16FE3AA7 Q30528487-203F362E-A1C5-4009-B147-FCBDF7DE80CF Q30537200-A511E00B-BF35-44FD-8AB0-87CBAACDBB96 Q30537889-35293EE2-2206-43A3-B145-6DEE1E4F3F52

P2860

Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo.

http://www.wikidata.org/entity/Q34546048

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Enhancement of capillary leaka ...... hiral S1P1 antagonist in vivo.

@ast

Enhancement of capillary leaka ...... hiral S1P1 antagonist in vivo.

@en

Enhancement of capillary leaka ...... hiral S1P1 antagonist in vivo.

@nl

type

label

Enhancement of capillary leaka ...... hiral S1P1 antagonist in vivo.

@ast

Enhancement of capillary leaka ...... hiral S1P1 antagonist in vivo.

@en

Enhancement of capillary leaka ...... hiral S1P1 antagonist in vivo.

@nl

prefLabel

Enhancement of capillary leaka ...... hiral S1P1 antagonist in vivo.

@ast

Enhancement of capillary leaka ...... hiral S1P1 antagonist in vivo.

@en

Enhancement of capillary leaka ...... hiral S1P1 antagonist in vivo.

@nl

P1433

Q34546048-4E5E1103-E94C-46C7-BBD4-AA124750CC9A

P1476

Q34546048-83463702-158D-4509-ABEE-C459F88A9E38

P2093

Q34546048-0E1A240D-E625-4F55-85DB-848B41383847

Q34546048-1C6F1D18-30EB-4E66-8840-8A76EC15BC3F

Q34546048-280F5C36-564E-46C1-8AA5-4251878B7BE9

Q34546048-3B6C953D-9331-4555-BC53-32A6E654628D

Q34546048-449954D8-9298-4097-8A90-383F9065EE22

Q34546048-485C69F0-D3BC-4983-B9F0-6877375D1C79

Q34546048-B6278AC7-95E5-4FE5-B3E5-E550D2F92BD3

Q34546048-D93258EA-32DA-4C69-AA35-5A5001E0E33F

Q34546048-E09CF2C1-BC65-411C-A6A3-9D8489D9294E

Q34546048-EE159B41-88A4-4B34-B398-9307134A0F8E

P2888

Q34546048-AE91A5EA-DDBC-42DC-B94B-209621FFA9E0

P304

Q34546048-105D12C6-91C7-4257-8A76-5940793A395D

P31

Q34546048-03132CAD-874F-454C-BBA3-457B10F06FD3

P356

Q34546048-A8114351-1265-4C09-AF5B-12B0F11CB8C7

P433

Q34546048-BBDC5116-300B-4336-BAB0-141853649157

P478

Q34546048-780BBD05-E3DA-47DC-B014-2E10F18D4E15

P50

Q34546048-0EA16038-F7ED-4CC7-BFAC-3781DE0E793A

Q34546048-3BE30AF6-E8FC-41F9-B05A-390AC14187D7

P577

Q34546048-908D7AAD-B1EB-4808-870C-45B3B4E11D27

P5875

Q34546048-6BBC37B9-41A8-466D-860D-69D76194B60A

P698

Q34546048-115DB3C9-1A7B-4A80-88DA-FAC13388F06B

P356

P1433

Nature Chemical Biology

P1476

Enhancement of capillary leaka ...... chiral S1P1 antagonist in vivo

@en

P2093

Chi-Huey Wong

http://www.w3.org/2001/XMLSchema#string

David Marsolais

http://www.w3.org/2001/XMLSchema#string

Euijung Jo

http://www.w3.org/2001/XMLSchema#string

Hugh Rosen

http://www.w3.org/2001/XMLSchema#string

Ian Parker

http://www.w3.org/2001/XMLSchema#string

M Germana Sanna

http://www.w3.org/2001/XMLSchema#string

Melanie P Matheu

http://www.w3.org/2001/XMLSchema#string

Michael D Cahalan

http://www.w3.org/2001/XMLSchema#string

Pedro J Gonzalez-Cabrera

http://www.w3.org/2001/XMLSchema#string

Sindy H Wei

http://www.w3.org/2001/XMLSchema#string

P2888

P304

434-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCHEMBIO804

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6955423

http://www.w3.org/2001/XMLSchema#string

P698

16829954

http://www.w3.org/2001/XMLSchema#string